eBook - ePub
Neuro-Oncology for the Clinical Neurologist E-Book
Roy E. Strowd
This is a test
Partager le livre
- 656 pages
- English
- ePUB (adapté aux mobiles)
- Disponible sur iOS et Android
eBook - ePub
Neuro-Oncology for the Clinical Neurologist E-Book
Roy E. Strowd
DĂ©tails du livre
Aperçu du livre
Table des matiĂšres
Citations
Ă propos de ce livre
In the growing field of neuro-oncology, the past few years have witnessed rapid advances in tumor classification, treatment modalities, and the role of neurologists and neuro-oncologists. Neuro-Oncology for the Clinical Neurologist is a first-of-its-kind resource that focuses on patient-clinical scenarios relevant to the practicing neurologistâbringing you up to date with everything from basic principles and neuro-oncology imaging consults to neurologic complications of radiation, systemic, and immune-based therapies, and much more.
- Focuses on the clinical management of patients typically encountered by neurologists and neurology trainees.
- Provides clinically relevant updates in five key areas of neuro-oncology: primary CNS tumors, brain and leptomeningeal metastases, inherited tumor syndromes of the nervous system (e.g. neurofibromatosis), paraneoplastic and immune-mediated neurological complications of cancer, and neurological complications of cancer treatments.
- Includes a summary of clinical pearls and a reference list of clinical cases.
- Anchors each chapter with patient cases and clinical scenarios, provides evidence-based discussion, and explains patient management.
- Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.
Foire aux questions
Comment puis-je résilier mon abonnement ?
Il vous suffit de vous rendre dans la section compte dans paramĂštres et de cliquer sur « RĂ©silier lâabonnement ». Câest aussi simple que cela ! Une fois que vous aurez rĂ©siliĂ© votre abonnement, il restera actif pour le reste de la pĂ©riode pour laquelle vous avez payĂ©. DĂ©couvrez-en plus ici.
Puis-je / comment puis-je télécharger des livres ?
Pour le moment, tous nos livres en format ePub adaptĂ©s aux mobiles peuvent ĂȘtre tĂ©lĂ©chargĂ©s via lâapplication. La plupart de nos PDF sont Ă©galement disponibles en tĂ©lĂ©chargement et les autres seront tĂ©lĂ©chargeables trĂšs prochainement. DĂ©couvrez-en plus ici.
Quelle est la différence entre les formules tarifaires ?
Les deux abonnements vous donnent un accĂšs complet Ă la bibliothĂšque et Ă toutes les fonctionnalitĂ©s de Perlego. Les seules diffĂ©rences sont les tarifs ainsi que la pĂ©riode dâabonnement : avec lâabonnement annuel, vous Ă©conomiserez environ 30 % par rapport Ă 12 mois dâabonnement mensuel.
Quâest-ce que Perlego ?
Nous sommes un service dâabonnement Ă des ouvrages universitaires en ligne, oĂč vous pouvez accĂ©der Ă toute une bibliothĂšque pour un prix infĂ©rieur Ă celui dâun seul livre par mois. Avec plus dâun million de livres sur plus de 1 000 sujets, nous avons ce quâil vous faut ! DĂ©couvrez-en plus ici.
Prenez-vous en charge la synthÚse vocale ?
Recherchez le symbole Ăcouter sur votre prochain livre pour voir si vous pouvez lâĂ©couter. Lâoutil Ăcouter lit le texte Ă haute voix pour vous, en surlignant le passage qui est en cours de lecture. Vous pouvez le mettre sur pause, lâaccĂ©lĂ©rer ou le ralentir. DĂ©couvrez-en plus ici.
Est-ce que Neuro-Oncology for the Clinical Neurologist E-Book est un PDF/ePUB en ligne ?
Oui, vous pouvez accĂ©der Ă Neuro-Oncology for the Clinical Neurologist E-Book par Roy E. Strowd en format PDF et/ou ePUB ainsi quâĂ dâautres livres populaires dans Medicina et NeurologĂa. Nous disposons de plus dâun million dâouvrages Ă dĂ©couvrir dans notre catalogue.
Informations
Sujet
MedicinaSous-sujet
NeurologĂaSection 1
Basic principles of neuro-oncology
Chapter 1: Fundamentals of neuropathology
Introduction to neuropathology and molecular diagnostics
Sonika Dahiya, and Shakti Ramkissoon
Introduction
In typical cases, the clinical workflow for brain tumors begins with imaging studies; however, despite the increased sensitivity and capabilities of these methodologies, diagnosing brain tumors requires histopathologic evaluation of tissue. It is imperative for clinicians to understand how brain tumors are classified so that they can better counsel patients at the time of initial presentation, accurately describe prognosis, and prioritize management of medical or neurological comorbidities based on the anticipated behavior of the tumor.
Tumor classification has historically relied primarily upon morphologic features identified by light microscopy. In the past decade, integration of high-throughput genomic testing into routine clinical workflows has refined the approach to diagnosing brain tumors. 1 In this chapter, we explore tumor classification from traditional microscope-based approaches to currently available methodologies. We review genomic profiling and introduce the concept of an integrated diagnosis.
The chapter begins with a discussion of the histologic assessment of brain tumors, which is often the first data to be reported after a tumor surgery. This is followed by a discussion of molecular profiling, which is used to further classify these tumors, guide prognosis, and predict response to therapy. Molecular data typically returns in the weeks following surgery. Finally, we review a series of common case scenarios and integrate the histologic and molecular data into a final integrated diagnosis that clinicians can use to help manage and counsel these patients.
Histologic classification of central nervous system tumors
The primary method of diagnostic neuropathology and brain tumor classification remains microscopic evaluation of hematoxylin and eosin (H&E)âstained tissue sections by light microscopy. This approach has experienced relatively few changes over the past several decades with generations of pathologists still undergoing specialized training focused on learning to read or interpret stained sections on glass slides.
The process of converting a portion of resected brain tissue to an H&E stained section is the first step to achieve a tissue-based diagnosis. Brain tissues removed at the time of surgery can range from small biopsies, such as needle core biopsies, to large resections that often occur during a tumor debulking surgery. Once the fresh tissue reaches the laboratory, the sample is subjected to fixation in formalin-based solutions that serve to preserve tissues and cells.
Formalin-fixed tissues then undergo a series of steps, commonly referred to as tissue processing, which prepares the formalin-fixed tissues for embedding into a block of paraffin wax. Once the tissue fragment is embedded in paraffin and mounted into a cassette, this âblockâ serves as the final medium where the tissue can be safely stored for years (even decades). Importantly, this processing method preserves the integrity of the tissues for later use. Formalin-fixed paraffin-embedded (FFPE) samples are the mainstay of both traditional microscopic analysis and serve as the starting medium for most tissue-based molecular and genomic assays currently available.
Once a tissue sample is converted to an FFPE block, sections (5 microns thickness) can be cut from the block, placed onto glass slides, and subjected to staining with the dyes hematoxylin and eosin. Hematoxylin stains nucleic acids a deep blue-to-purple color, which readily highlights the nuclei of cells. Eosin stains other cellular components, like proteins, with a bright pink color that contrasts with the blue hematoxylin-stained nucleiâtogether these two dyes serve as the basis for all H&E-based tumor classification.
Brain tumor classification based on H&E features relies on the fact that the histologic appearance of these tumors is consistent from one patient to another. In fact, the features are so reproducible that they have been codified into the World Health Organization (WHO) Classification of Tumors of the Central Nervous System, which outlines the microscopic features present in all brain tumors and serves as the central resource to ensure all patients around the world are diagnosed and graded using the same criteria.
Tumor Grading. Unlike other tumors, which are staged based on size, lymph node involvement, and presence or extent of metastases (e.g., TNM classification), staging is not used for gliomas, which rarely spread beyond the central nervous system (CNS). Instead, gliomas are graded from grade I to IV and are broadly divided into low- and high-grade tumors. Grade I and II are considered âlow gradeâ and grade III and IV as âhigh gradeâ; of these, grade I tumors are generally well circumscribed, whereas grades IIâIV are diffusely infiltrating, albeit with some exceptions such as ependymoma and pleomorphic xanthoastrocytoma which tend to be well circumscribed despite conforming to grade II. The histologic features assessed to establish glioma grading include atypia, mitoses, endothelial or microvascular proliferation, and necrosis. Grade I tumors such as pilocytic astrocytomas are most commonly encountered in the pediatric setting. Although such tumors do occur in the adult population, the use of the term âlower-grade gliomasâ in adults largely refers to infiltrating grade II tumors such as diffuse astrocytoma and oligodendroglioma. Grade III tumors include anaplastic astrocytoma (AA3) and anaplastic oligodendroglioma (AO3), whereas glioblastoma (GBM) is considered a grade IV astrocytoma. Progression of brain tumors from low to high grade does occur, most commonly in adul...